Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies

Journal of Clinical Oncology

Volumn 18, Issue 20, 2000, Pages 3553-3557

  Madajewicz, S ^a   Hentschel, P ^a   Burns, P ^a   Caruso, R ^a   Fiore, J ^a   Fried, M ^a   Malhotra, H ^a   Ostrow, S ^a   Sugarman, S ^a   Viola, M ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SOLID TUMOR;

EID: 0034668075     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.20.3553     Document Type: Article

References (9)

1. Preclinical characteristics of gemcitabine
2. A phase I trial of high dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer
3. Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea
4. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
5. Pharmacologically directed strategy for dose intensification of gemcitabine: A phase I trial
6. Advanced colorectal cancer: Which regiments should we recommend?
7. Weekly irinotecan (CPT-11), leucovorin (LV) and fluorouracil (FU) is superior to daily x 5 LV/FU in patients (PTS) with previously untreated metastatic colorectal cancer (CRC)
8. Evaluation of the addition of oxaliplatin (OXA) to the same Mayo or German 5-FU regimen in advanced refractory colorectal cancer (ARCRC)
9. Gemcitabine future prospects of single-agents and combination studies